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I t  73-3 Hel ical  Atheractomy for In-Brant Restenosis: Acute and 
Long-Term Results From the Helixcision TM 
EndoLumlnal In-Stent Excision (HELIX I) International 
Feas ib i l i ty  Trial 
Mamoo Nakamura, Andrew J. Carter, Yasuhiro Honda, Alexander Abizaid, Arne Torte, 
Eberhard Grupa, Paul G. Yock, Alan C. Yaung, Peter J. Fitzgerald, The HELIX I 
Investigators, Stanford Universi~ Stanford, California. 
Background: The Helixcision TM EndoLuminal In-stent Excision (HELIX I) Intemational 
Feasibility trial is a prospective multi-center egistry to test a new helical atherectomy 
device for the treatment of in-stent restenosis. The primary endpoint of this study is the 
safety of this device defined as major adverse cardiac events (MACE) at 30 days. The 
secondary endpoints are target lesion revascularization (TLR) and angiographic binary 
restenosis at 6-month follow-up. 
Methods: In HELIX f, 32 in-stent restenosis lesions (17.2±11.4 mm in mean lesion 
length) in 32 patients ware treated with Halixcision followed by balloon angioplasty. The 
debulking efficacy was assessed with serial IVUS (pra, post-HeUxcision and post-adjunc- 
tive balloon) in a subset of 18 lesions. To further investigate the longitudinal efficacy, 3D 
analysis was also performed in 12 lesions with automated pullback to calculate average 
cross-sectional areas across the stant. 
Reaults: At baseline, the angiographic reference diameter was 2.60±0.46 mm. Minimum 
lumen diameter improved from 0.84±0.33 to 2.19±0.41 mm (p<0.0001). IVUS showed a 
relative reduction of intimal area (IA) by 39±19% (from 4.99±2.04 to 2.98±1.47 mm 2, 
p<0.0001) after Helixcision; adjunctive balloon angioplasty resulted in a total reduction of 
50±16% (to 2,44±1.09 mm 2) at the site of minimum lumen area. The degrees of IA 
reduction were closely similar in 3D analysis. To date, 30-day and 6-month clinical follow- 
up is available in 97% and 72% of the enrolled patients, respectively. At 30-day follow-up, 
no MACE was reported except for CK elevation in 2 patients (6%) within f day after pro- 
cedure. TLR within 6 months was performed in 6 patients (26%). Angiographic follow-up 
data will be also presented. 
Conclusions: Preliminary results of HELIX I indicate that helical atherectomy is safe and 
feasible for the treatment of in-stant restenosis. The concordant results between 2D and 
3D IVUS analyses suggest that this unique technology can achieve uniform longitudinal 
dabulking throughout he stant. The long-term outcomes appeared to be favorable, con- 
sidering the relatively diffuse lesion morphology in the small vessels in this trial. 
1173-4 The Influence of Diabetes on Long-Term Cl in ica l  
Outcome Following Percutaneoua Coronary 
RevascularlzaUon for Single Vessel Disease 
Meyer Elbaz. Dakher Lahidheb, Robert Hobeika, Philippe Uzzan, Eric Maupas, Joelle 
Fourcada, Jacques Poel, Didiar Cardd, Cardiology, Purpan Hospital Toulouse, France. 
Background : Diabetics have more often extent of coronary artery disease (CAD) and 
less favorable outcomes after any form of revasculadzation. However, in comparison with 
non diabetic (ND) patients, the long-term survival in diabetic (D) patients type II who 
underwent parcutanaous coronary intervention (PCI) for single vessel disease (SVD) has 
not been validated. 
Methods : Between April 1995 and March 1996, we analyzed a cohort of 533 consecutive 
patients with SVD who were treated with PCI and divided into ND (n = 437 pts) versus D 
(n = 87 pts) groups respectively. Clinical and angiographic baseline characteristics were 
similar between the two groups and global left ventricular(LV) function was sub-normal 
(54.6 % versus 55.8 %, p = ns). 
Mean follow-up interval was 50 ± 13.5 months. The primary end-point of follow-up was 
death of any cause and secondary end-point was cardiac death, target lesion revascular- 
ization (TLR), major adverse cardiac events (MACE) and extent of CAD. Survival rates of 
the two groups were estimated by the Kaplan-Meier method. 
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ND Group D Group p 
(n = 437 pts) (n = 87 pts) 
Death 44 (10.1%) 17 (19.5 %) 0.01 
Cardiac Death 22 (5 %) 16 (18.4 %) < 0,0001 
TLR 83 (19 %) 16 (18.4 %) ns 
MACE 139 (31.8 %) 39 (44.8 %) 0.02 
Extent of CAD 49 (11.2 %) 18 (20.7 %) 0.009 
Conclusion ; In comparison with non diabetic patients and in spite of pre-spacified CAD 
(PCI for SVD), diabetes mellitus is associated with worse long-term outcome and 3-fold 
higher rate of cardiac mortality. 
1173-5 Impact  o f  Renal Function on Morbidity and Morta l i ty  
After Percutaneous Saphenous Vein Graft Intervention 
Luis Gruberg, Nail J. Weissman, Augusto D. Pichard, Ron Waksman, Kenneth M. Kent, 
Lowell F. Satler, William O. Suddath, Hongshang Wu, Joseph Lindsey, Jr., Washington 
Hospital Center, Washington, DisL of Columbia, Rambam Medical Center, Hails, israel. 
Background: Percutaneous coronary intervention in patients with chronic renal insuffi- 
ciency (CRI) and native coronary artery disease is often problematic, marred by 
increased mortality, morbidity and revascularization procedures. Little is known about the 
effect of CRI on patients who undergo saphenous vein graft (SVG) intervention. Meth- 
ods: We analyzed 1,265 consecutive patients who underwent percutaneous SVG inter- 
vention and divided them into four groups based on calculated craatinine clearance 
(CrCI): Group 1, CrCI>70 ml/min (n=626); Group 2, CrCi=50-69 ml/rnin (n=357); Group 3, 
CRC1=30-49 ml/min (n=228) and Group 4 ; CrCI<30 ml/min (n=54). Patients on dialysis 
were excluded from the study. Results: Patients with lower CrCI were more often older, 
female, diabetics and had worse left ventricular function. Overall immediate procedural 
success was similar for all groups. In-hospital and one-year outcomes are shown in the 
Table. By multivariate regression analysis, CrCI was an independent predictor of late 
mortality. Conclusion: This study suggests that renal function is a primary determinate in 
short- and long-term survival in patients undergoing percutaneous SVG intervention and 
there is a clear relationship between CrCI and cardiovascular outcome. 
Group I Group 2 Group 3 Group4 p 
(n=626) (n=357) (n=228) (n=54) 
In-hospital death 0.3 % 1.5 % 2.2 % 7.1% <0.001 
In-hospital cardiac death 0.1% 1.1% 1.5 % 2.4 % 0.002 
12-month death 7.1% 8.0 % 19.0 % 36.7 % <0.001 
12-month cardiac death 66.0 % 80.7 % 63.2 % 54.6 % <0.001 
1173-6 Ef fect  of Postmenopausal Hormone Therapy on Major  
Adverse Cardiac Events After Percutaneous Coronary 
Intervention: The HERS Trial 
Masrcor A. Khan. Michael G. Shlipak, Ming W. Liu, William J. Rogers, Feng Lin, Mark A. 
Hlatky, University of Alabama at Birmingham, Birmingham, Alabama, University of 
California San Francisco, San Francisco, California. 
OBJECTIVES: To determine the effect of post-menopausal hormone therapy (HRT) on 
coronary heart disease (CHD) events after percutaneous coronary interventions. 
BACKGROUND: In observational studies, HRT with estrogen has been associated with 
a reduced incidence of major adverse cardiac events (MACE) after percutaneous coro- 
nary interventions (PCI) in postmenopausal women. No clinical trial has studied the 
effects of post-menopausal HRT after percutaneous coronary intervention. 
METHODS: The Heart and Estrogen/progestin Replacement Study (HERS), was a ran- 
domized clinical trial of hormone therapy for CHD prevention in post-menopausal women 
with known CHD. During HERS follow-up, 357 participants underwent percutaneous cor- 
onary intervention, 175 in the HRT arm and 182 on placebo. This study compared the 
incidence of MACE subsequent to PCI among participants assigned to HRT and pla- 
cebo. 
RESULTS: Among the women who underwent PCI, baseline characteristics were similar 
between those in the HRT and placebo groups. Mean follow-up duration was 27 months 
for HRT group and 25 months for placebo group (p=0.50). During follow-up, 70 (40%) 
women in the HRT group and 72 (40%) women in the placebo group experienced a CHD 
event (RR=0.97; 95% Ch 0.70 - 1.35). No differences were observed in the incidences of 
target lesion rovascularization (27% vs. 30%; p=0.64), unstable angina (10% vs. 10%; 
p=0.90), myocardial infarction (7% vs 10%; p---0.31), or CHD death (6% vs. 5%; p=0.75). 
After multivariate analysis, only diabetes was a significant predictor of CHD events 
(RR=1.85; 95% Ch (1.26 - 2.72), 
CONCLUSION: In contrast to prior observational studies, HRT had no effect on major 
adverse Cardiac events after percutaneous coronary interventions in the HERS trial. 
1173-7 Predictors of Contrast Induced Nephropathy After 
Percutaneoua Coronary Intervention in Patients With 
and Without Chronic Renal Fai lure 
Ioannis lakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjazi, D. Ashby, J. Forman, M 
Guiry, R. Brendwein, M. Losquadro, T. Limpijankit, G. W. Stone, J, W. Moses, M. B. Leon, 
R. Mehran, Cardiovascular Research Foundation, Lenox Hill Heart & Vascular Institute, 
New York, New York. 
Background: Contrast induced nephropathy (CIN) has been associated with unfavorable 
early and late outcome. We determined predictors of CIN in patients with and without 
chronic renal failure (CRF), defined as baseline serum craatinina >1,5 mg/dl. 
Methods and Results: Of a total 8268 consecutive patients who underwent PCI (Jan 
1994 to July 1999), 1431 (16.5%) developed CIN (25% rise in serum creatinine com- 
pared to pre-PCI). Creatinina clearance was calculated by the Cookcroft formula. 
Independent predictors of CIN derived by stepwise logistic regression analysis for both 
groups (Table). 
Conclusions. Baseline clinical characteristics and creatinine clearance (not serum craati- 
nine value) predict CIN development after PCI. Meticulous CIN preventive measures 
should be targeted in the high-risk patients. 
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Multivadate Predictors of Patients without CRF Patients with CRF 
CIN OR (95%CI), p-value OR (95%Ci), p-value 
Diabetes 1.45 (1.26-1.67) 1.78 (1.34-2.37) p<0.0001 
p<0.O001 
Severe CHF 3.44 (2.54-4.65) 2.41 (1.55-3.73) p<0.0001 
p<0.0001 
Contrast/BSA ratio 1.02 (1.01=1.02) 1.01 (1.00-1.01) p<0.0001 
p<0.0001 
Creatinine Clearance 1.02 (1.01-1.02) 0.98 (0.98-0.99) p=0.0003 
p<0.0001 
Female Gender 1.25 (1.08-1.43) p=NS 
p=0.0047 
Age 1.04 (1.03-1.05) p=NS 
p<O.0001 
1173-8 Intracoronary Beta-Radiation Therapy for Long Lesions 
in Native Coronary Vessels 
Goran R. Stankovic, Antonio Colombo, Carlo Di Mado, Remo AIbiero, Nicala Corvaja, 
Takuro Takagi, Konstantinos Toutouzas, Antonio Amato, Ginevra Sivied, Roberto 
Orecohia, Centro Cuore Columbus, Milan, Italy 
Background: This study evaluates early and late clinical and angiographic outcome of 
patients with long (>20mm) de novo or in-stent restenotic lesions in native coronary ves- 
sels treated with beta radiation for restenosis prevention. 
Methods and results: Between April 1999 and December 2000, 84 consecutive patients, 
with 117 lesions longer than 20ram in native coronary vessels, were successfully treated 
using 90-Strontium/Yttrium radiation source. The reference vessel size was 2.49±0.5 
mm, and the mean lesion length 28.7±8.6 mm. Stents were implanted in 43.6% of the 
lesions. Radiation dose delivered was 16.5±3.3 Gy at 2 mm from the center of the 
source, with a mean dwell time of 269¢122 sac, and using manual pullback technique in 
21% of lesions. Ticlopidine was prescribed for 3 months in the first 29 patients, subse- 
quently for 6 months without stenting or for 1 year with stent implantation. Clinical follow- 
up was obtained for all patients after 16.4±6.7 months. Major adverse cardiac events, a 
composite of death, Q-wave myocardial infarction and target lesion revascularization, 
occurred in 19 patients (22.6%). Late thrombosis occurred in 2 patients (2.4%) treated 
with stents at the time of radiation, and after discontinuation of ticlopidine. 
Follow-up angiography was performed in 74 patients (88%). Angiographic restenosis 
(>50% diameter stenosis of the analysis segment) was present in 27/103 lesions 
(26.2%). Target lesion and target vessel revasculadzation rates were 21.4% and 30.8%, 
respectively. 
Conciusiom Intracoronary beta radiation can be safely and effectively used to treat long 
coronary lesions. Long term combined antipiatelet herapy is necessary for patients who 
receive new stents at the time of the radiation treatment. 
1173-9 Efficacy of Long Radiation Treatment in Native In-Stent 
Restenosis: A Subanalysis From the RENO Registry 
Dietrich Baumoart. T. Limpijankif, P. Serruys, A. Colombo, S. Silber, E. Eeckhout, P. 
Urban, R. Bonan, A. Zeiher, A. H. Gershlick, G. Dangas, A. A. Lansky, R. Mehran, G. W. 
Stone, M. B. Leon, Cardiovascular Research Foundation, New York, New York, 
University of Essen, Essen, Germany. 
Background: The effectiveness of intracoronary radiation therapy of diffuse in-stent rest- 
enosis (ISR) with Strontium-90 Beta sources is unknown. 
Methods: The RENO registry is a post market prospective surveillance study enrolling 
consecutive patients with iSR at 46 European centers using the Novoste Beta-Cath TM 
system. Patients were treated with approved interventional devices, followed by Stren- 
tium-9O Beta-radiation treatment. Of the 1098 patients enrolled in the trial, 139 had dif- 
fuse native coronary ISR treated with a stepping technique using a 30, 40, or 60mm 
source train or a single 60mm source train. The historical control group was the placebo 
arm of the WRIST and LONG WRIST studies (N=94). 
Results: Baseline characteristics were similar between two groups except for more dia- 
betics in placebo. Brachytherapy success (<50% residual stenosis and successful deliv- 
ery of the radiation device) was 99.3% in the RENO group. Clinical follow-up at 6 months 
was available in >96%. The results are shown in the table. 
Conclusion: Beta-radiation with Sr-90 using either a stepping (pullback) technique or a 
single 60mm source train to treat patients with diffuse, long native ISR lesions is effective 
and results in significant reductions in TVR by 75% and MACE by 72% without any 
increase in the late thrombosis rates compared to historical controls. 
RENO Long Radiation WRIST Placebo p-Value 
(N=139) (N=94) 
Diabetes (%) 21.9% 37.2% 0.02 
Lesion length (mm) 35.33 ± 17.89 27.97 ± 11.84 0.0003 
TVR at 5 months 14.9% 60.6% <0.0001 
MACE at 6 months 17.9% 64.9% <0.0001 
Total occlusion at 6 months 12.2% 9.9% NS 
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1173-10 Feasib i l i ty  and Safety  of  a Novel  Cryoang iop leaty  
System 
Mitsuvasu Terashima, Yasuhiro Honda, Frederick S. Goar, James D. Joye, Kristine 
Tatsutani, Margaret Yoklavich, Paul G. Yock, Peter J. Fitzgerald, Stanford University 
Stanford, California. El Cam/no Hospital, Mountain View, California. 
Background: Previous cryosurgical studies have indicated that freezing arterial tissues 
in vivo is followed by a benign healing process largely devoid of neointimal proliferation, 
suggesting a potential beneficial impact on restenosis following intervention. This study is 
designed to evaluate feasibility and safety of a newly developed cryoangioplasty (CP) 
system in a porcine coronary model. 
Methods: The cryoangioplasty system (CryoPlasty TM, CryoVascular Systems, Inc.) con- 
sists of a baltoon-besed catheter and an inflation unit, which delivers tiqutd nitrous oxide 
through the catheter and inflates the balloon to a predetermined pressure and tempera- 
ture. We assessed the safety and performance characteristics of CP system at a sub- 
zero treatment emperature, compared with those of e control treatment (conventional 
PTCA) using a similar balloon to artery ratio and pressure conditions. Twelve animals 
were assigned to 3-day or 28-day follow-up (6 animals per group). Each animal under- 
went PTCA in one of the coronary arteries and CP in up to two of the remaining arteries 
(6 vessels with PTCA in both groups, 9 vessels and 12 vessels with CP in 3-day and 28- 
day follow-up, respectively). Angiogrephy was performed at baseline, following treat- 
ment, and follow-up, and changes in lumen diameter and % diameter stsnosis were ana- 
lyzed by quantitative coronary angiography. 
Results: No adverse events (including side branch occlusion or distal coronary flow limi- 
tation) were observed in any group. No significant loss of lumen diameter or increment of 
% diameter stsnosis was found at either 3-day or 28-day follow-up in the CP group. At 
28-day follow-up, mean % diameter stenosis in the CP group was 4.6%, compared with 
12.5% in the PTCA group (p<0.05). 
Conclusions: This study demonstrates the feasibility and safety of the cryoangioplasty 
system for use in the coronary arteries and a possible beneficial effect on chronic vascu- 
lar reaction following intervention. 
11 73-11 Are Older Women, Compared to Older Men, at Higher 
Risk During Percutaneous Coronary Intervention? 
Results From the Danish PTCA Registry 
Lisette O. Jensen. Per Thayssen, Eli Kassis, Klaus Rasmussen, Karl Saunam&ki, Leif 
Thuesen, Department of Cardiology Odense University Hospital, Odense, Denmark. 
BackgroundOIder patients are at higher risk during percutaneous coronary intervention 
(PCI). Whether this increased risk is gender related is not known. In order to evaluate this 
issue further, data from the Danish PTCA Registry were analysed for the 3-year period 
1996-1998. During this period data from all PCI procedures in Denmark were prospec- 
tively recorded in a central database. 
Methods Angiographic baseline characteristics, outcome of PCI and procedural compli- 
cations were analysed in a total of 8.187 consecutive procedures (6.896 patients, 11.472 
lesions dilated). 
Results In patients <_ 70 year women were significantly older than men (58.0 vs. 56.5; p 
< 0.0001), but no significant gender difference in age was seen in patients • 70 year. 
< 70 year > 70 year p 
men women men women 
Number of patients 5.242 1.654 822 469 
Age (Year) 56.5 58.0 74.8 75.0 
Left ventricle ejection fraction (%) 60.3 62.1 56.5 61.1 
Coronary narrowing severity (%) 84.6 83.2 84.8 84.2 
Number of 1 vessel disease (%) 60.1 69.2 45.5 53.9 
Angiographic primary success 87.8 89.2 87.1 85.8 
rate (%) 
Rate of stenting (%) 58.1 56.2 58.6 57.9 
MACE (%) 4.2 4.9 8.4 10,4 
Emergency CABG (%) 0.9 1.0 1.0 1.3 
Myocardial infarction (%) 2.9 3.7 5,8 6.6 
Death (%) 0.4 0.2 1.6 2,6 
M = men, w = women; MACE = major adverse coronary events (emergency CABG, non- 
fatal myocardial infarction (q-wave and non-q-wave myocardial infarction), and death) 
within 24 hours after index procedure. 
*age but not gender as independent predictor, p < 0.0001 
**age and gender as independent predictor, p < 0.0001 
Logistic regression analysis showed, that age, but not gender, was an independent pre- 
dictor of angiographic primary success rate, MACE, myocardial infarction and death. 
ConcluslonOIder patients had significant more complications after PCI, however no sig- 
nificant gender difference with regard to complications after PCI, neither in patients -< 70 
year nor in patients > 70 year could be demonstrated. 
